<DOC>
	<DOCNO>NCT01467466</DOCNO>
	<brief_summary>The purpose research study compare effectiveness intravenous isotonic sodium bicarbonate intravenous isotonic sodium chloride oral N-acetylcysteine oral placebo prevention serious adverse outcome follow angiographic procedure high-risk patient .</brief_summary>
	<brief_title>Prevention Serious Adverse Events Following Angiography</brief_title>
	<detailed_description>The intravascular administration iodinate contrast medium diagnostic image common cause acute kidney injury ( AKI ) lead cause iatrogenic renal disease . Contrast-induced AKI associate serious adverse outcome include death , need dialysis , prolonged hospitalization , acceleration rate progression underlie chronic kidney disease . The benefit IV isotonic bicarbonate compare IV isotonic saline N-acetylcysteine prevention contrast-induced AKI associate adverse outcome remain unclear . The purpose trial compare effectiveness IV isotonic sodium bicarbonate IV isotonic sodium chloride oral NAC placebo prevention serious adverse outcome 7,680 high-risk patient schedule undergo coronary non-coronary angiography . Using 2 x 2 factorial design , patient randomize receive : 1 ) either peri-procedural IV isotonic sodium bicarbonate peri-procedural IV isotonic saline 2 ) either oral NAC oral placebo prior 5 day follow angiographic procedure . The primary study endpoint composite outcome comprise death , need acute dialysis , persistent decline kidney function within 90 day follow index angiogram .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>Planned elective urgent coronary noncoronary angiography iodinate contrast medium anticipate interval 3 hour identification indication angiography time plan procedure . Preangiography eGFR &lt; 60 ml/min/1.73 m2 diabetes mellitus preangiography eGFR &lt; 45 ml/min/1.73 m2 without diabetes mellitus Ability provide inform consent Stage 5 CKD ( eGFR &lt; 15 mL/min/1.73 m2 ) Currently receive hemodialysis , peritoneal dialysis , continuous renal replacement therapy , sustain low efficiency dialysis ( SLED ) Unstable baseline SCr ( know ) time angiography define increase SCr 25 % 3 day prior angiography Decompensated heart failure require follow therapy time angiography : IV milrinone , amrinone , dobutamine , nesiritide Isolated ultrafiltration therapy Intraaortic balloon pump Emergent angiography procedure define anticipated duration &lt; 3 hour identification indication angiography time plan procedure . Receipt intravascular iodinate contrast within 5 day precede angiography Receipt oral IV NAC within 48 hour precede angiography Known allergy Nacetylcysteine ( NAC ) Known anaphylactic allergy iodinate contrast medium Prisoner Age &lt; 18 year Pregnancy Ongoing participation unapproved concurrent interventional study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>renal</keyword>
	<keyword>cardiovascular</keyword>
	<keyword>kidney</keyword>
	<keyword>heart</keyword>
	<keyword>clinical trial</keyword>
	<keyword>double-blind</keyword>
	<keyword>multi-site trial</keyword>
	<keyword>randomize</keyword>
	<keyword>drug treatment</keyword>
	<keyword>IV solution</keyword>
	<keyword>antioxidant</keyword>
</DOC>